Hubbry Logo
Vi capsular polysaccharide vaccineVi capsular polysaccharide vaccineMain
Open search
Vi capsular polysaccharide vaccine
Community hub
Vi capsular polysaccharide vaccine
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Vi capsular polysaccharide vaccine
Vi capsular polysaccharide vaccine
Vi capsular polysaccharide vaccine
View on Wikipedia
from Wikipedia
Vi capsular polysaccharide vaccine
Vaccine description
TargetTyphoid
Vaccine typePolysaccharide
Clinical data
Trade namesTypherix, Typhim VI
AHFS/Drugs.comMultum Consumer Information
Routes of
administration		intramuscular injection, subcutaneous injection[clarification needed]
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 ☒NcheckY (what is this?)  (verify)

The Vi capsular polysaccharide vaccine (or ViCPS) is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid (another is Ty21a). The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine.

Medical uses

[edit]

The vaccine may be used in endemic areas in order to prevent typhoid. It is also commonly used to protect people who are traveling to parts of the world where typhoid is endemic.[citation needed]

Dosing

[edit]

The vaccine is injected either under the skin or into a muscle at least seven days before traveling to the typhoid-affected area (the CDC recommend 14 days). The vaccine is not effective in children under the age of two. To maintain immunity, the vaccine should be repeated every three years.[citation needed]

Efficacy and duration of protection

[edit]

The vaccine offers effective protection the first year after being given (with between 50% and 80% efficacy), second year (31% to 76%), and third year cumulative efficacy of around 55%.[1]

Biology

[edit]

The Vi polysaccharide, or Vi antigen, is part of the bacterial capsule found outside of the typhoid bacterium, Salmonella enterica subsp. enterica ser. Typhi. It is produced by the action of a single gene cluster in the cytoplasm and transported to the surface. This antigen contributes to much of typhoid's virulence, and is important for the infection of intestinal epithelial cells. It is also produced by S. enterica ser. Paratyphi C, the causative agent of paratyphoid fever C.[2]

Trade names

[edit]

Research

[edit]

A newer conjugate form of the vaccine (Vi bound to a non-toxic recombinant Pseudomonas aeruginosa exotoxin A, or Vi-rEPA) has enhanced efficacy,[3] including protection of children under 5 years of age.

The typhoid conjugate vaccine ("Typbar-TCV") is another Vi-based conjugate vaccine, in this case linked to Tetanus toxoid. It has been approved.[4]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Vi capsular polysaccharide vaccine

View on Grokipedia
from Grokipedia
The Vi capsular polysaccharide vaccine (ViCPS) is an injectable vaccine designed to protect against , a systemic caused by the bacterium serovar Typhi. It consists of purified Vi capsular polysaccharide antigen extracted from the , which stimulates the production of protective antibodies without using live or whole-cell components. First licensed in 1994, ViCPS represents a safer alternative to earlier heat-phenol-inactivated whole-cell typhoid vaccines, which were associated with significant reactogenicity. Developed through advancements in polysaccharide vaccine technology, ViCPS targets the Vi antigen, a virulence factor that helps S. Typhi evade phagocytosis and survive within host macrophages. Clinical trials in endemic areas, such as and , demonstrated its immunogenicity and protective efficacy, leading to prequalification by the (WHO) for use in high-burden regions. Unlike conjugate vaccines that link the Vi polysaccharide to a protein carrier for enhanced T-cell dependent immunity—particularly in young children—ViCPS induces a T-cell independent response, primarily generating IgG anti-Vi antibodies that correlate with protection. Administration involves a single 0.5 mL intramuscular dose containing 25 μg of Vi polysaccharide, ideally given at least two weeks before potential exposure, with boosters recommended every two years (per U.S. Advisory Committee on Practices) or three years (per WHO) for ongoing risk. Efficacy estimates range from 55% to 72% over 2–3 years in adults and children, with higher protection observed in some pediatric trials (up to 80% in children aged 2–4 years in , ). The vaccine is approved for individuals aged 2 years and older, showing comparable immunogenicity across age groups, though it does not confer protection against paratyphoid fevers caused by other serovars. ViCPS is recommended by the CDC and WHO for travelers to typhoid-endemic areas (primarily and ), household contacts of chronic carriers, and laboratory personnel handling S. Typhi. It is generally well-tolerated, with local reactions such as injection-site pain (up to 77%) and swelling being the most common adverse effects, and no serious systemic events reported in large-scale studies. While effective in outbreak control and short-term prevention, its limitations in duration and pediatric efficacy have spurred development of improved typhoid conjugate vaccines (TCVs), which offer longer-lasting immunity and are now preferred in routine programs in endemic countries.

Indications and contraindications

Primary indications

The Vi capsular polysaccharide vaccine is recommended for adults and children aged 2 years and older who are traveling to or residing in typhoid-endemic areas, including parts of (such as , , and ), other regions of , sub-Saharan , and , where exposure to Salmonella Typhi through contaminated food and water is a significant risk. It is particularly indicated as a prophylactic measure for high-risk groups, such as deployed to endemic zones, workers in outbreak-prone settings, household contacts of documented typhoid carriers, and laboratory personnel handling S. Typhi, to mitigate the potential for in these scenarios. This vaccine forms part of a comprehensive prevention strategy against Salmonella Typhi infection and is not a substitute for rigorous adherence to safe food and water practices, such as consuming only boiled or and avoiding uncooked foods in high-risk environments. In providing moderate protection of 50-80% against bacteremic during the first year after vaccination, it targets the Vi antigen to induce immunity, though ongoing measures remain essential.

Contraindications and precautions

The Vi capsular polysaccharide vaccine is contraindicated in individuals with a known history of severe allergic reaction (e.g., ) to a previous dose or to any vaccine component, including the phenol preservative used in formulations such as Typhim Vi. The vaccine is not recommended for children younger than 2 years of age due to inadequate and poor observed in infants. Vaccination should be delayed in persons experiencing a moderate or severe acute febrile illness, as this is a general precaution for all to avoid confounding symptoms or reduced response; mild illness does not preclude administration. Caution is advised when administering the vaccine to immunocompromised individuals, such as those with infection, although it is not absolutely contraindicated and is preferred over live attenuated alternatives due to its inactivated nature. In pregnant women, the vaccine should be administered only if the potential benefits outweigh the risks, as data on are limited, though no of fetal harm has been reported; it is generally deferred unless travel to high-risk areas necessitates protection. For individuals, the vaccine is considered safe with no impact on or , as inactivated vaccines do not pass into in quantities that affect the recipient or nursing child. The Vi polysaccharide may be co-administered with most other inactivated or live vaccines without interference.

Administration

Dosing regimen

The Vi capsular (ViCPS) is administered as a single primary dose of 0.5 mL containing 25 µg of purified Vi , given intramuscularly to individuals aged 2 years and older. No priming doses or multi-dose series are required for initial , as the elicits a direct response without the need for prior . The is not approved or recommended for children under 2 years of age due to limited in this group, where typhoid conjugate vaccines may be considered as alternatives for younger children at risk. For optimal protection, the primary dose should be administered at least 14 days prior to potential exposure to , such as during travel to endemic areas, to allow sufficient time for development. Booster doses of 0.5 mL are recommended every 2 years for individuals with ongoing or repeated risk of exposure, as levels wane after approximately 2 years. Some guidelines suggest boosters every 2 to 3 years based on varying assessments of protection duration. The vaccine must be stored refrigerated at 2–8°C (36–46°F) and protected from light; it should not be frozen, as freezing may render it ineffective.

Route and preparation

The Vi capsular polysaccharide vaccine is administered by intramuscular () injection, with subcutaneous (SC) injection as an acceptable alternative route. For adults, the preferred IM site is the deltoid region; in children aged 2 years and older, the anterolateral aspect of the thigh is recommended. Intravenous injection or administration into the gluteal area must be avoided to prevent complications. The is provided as a 0.5 mL single-dose or pre-filled containing a clear, colorless, sterile solution of purified Vi polysaccharide (25 μg per dose); no reconstitution or dilution is required. Prior to use, the container should be shaken vigorously to obtain a uniform suspension, and it must be visually inspected for discoloration or particulate matter—do not administer if either is present, and discard accordingly. The should be stored refrigerated at 2°C to 8°C and protected from light, without freezing. Following administration, patients should be observed for 15 minutes to monitor for immediate reactions, with facilities for managing readily available. The vaccine is compatible with co-administration of other inactivated at separate anatomic sites but should not be mixed in the same ; it is not recommended for simultaneous use with the live oral .

Efficacy and safety profile

Clinical efficacy

The Vi capsular polysaccharide (Vi CPS) vaccine has demonstrated protective efficacy of 50-80% against in the first year following vaccination, based on randomized controlled s conducted in endemic areas. In a double-blind in in 1986–1987 involving 23,075 children aged 5–14 years, the vaccine showed 64% efficacy against culture-confirmed from six weeks post-vaccination through 21 months of follow-up compared to a control. A randomized double-blind in from 1986–1988 reported 74% efficacy (95% CI 49–87%) against blood culture-confirmed over 20 months among 6,908 residents in high-incidence villages. Protection conferred by the Vi CPS is primarily against bacteremic , with limited impact on chronic Typhi carriage, as the vaccine targets the Vi expressed during systemic but not in colonization. Observational studies have reported field effectiveness ranging from 53% to 87% among travelers and residents in endemic regions; for instance, a cluster-randomized trial in , , found 61% effectiveness over two years in urban children and adults. Among U.S. travelers to , effectiveness was estimated at 80% based on data from 2008-2011. A 2024 systematic and of five randomized controlled trials estimated pooled efficacy of 58% (95% CI 44–69%) against culture-confirmed over 1–3 years post-vaccination (moderate certainty evidence). A key limitation of the Vi CPS vaccine stems from its T cell-independent immune response, which elicits primarily IgM and short-lived IgG antibodies without inducing memory B cells, resulting in weaker and less durable immunity in young children under two years of age compared to T cell-dependent conjugate vaccines. This response also contributes to shorter overall protection relative to conjugates, though initial efficacy remains substantial in older children and adults.

Duration of immunity

Protective immunity following administration of the Vi capsular polysaccharide vaccine typically peaks 2–4 weeks after , with protective antibody levels detectable as early as 7 days post-. Clinical is estimated at 50–80% during the first year, declining to 31–76% in the second year, and reaching approximately 55% cumulatively by the third year, based on pooled data from multiple randomized controlled trials. Serum anti-Vi IgG levels, which serve as a marker of , rise significantly post-vaccination but decline rapidly thereafter, often within 6–12 months, to levels below protective thresholds in many recipients, thereby necessitating booster doses every 2–3 years to maintain immunity. Several factors influence the duration of immunity induced by the , including age, with shorter persistence observed in elderly individuals due to reduced of polysaccharide antigens in older adults; endemic exposure to Typhi, which may provide natural boosting of levels; and pre-existing baseline immunity, which can modulate the magnitude and longevity of the vaccine-induced response. A serological correlate of protection is an anti-Vi IgG concentration of approximately 3–4 μg/mL, which is initially achieved in 70–90% of vaccinees shortly after immunization. Longitudinal studies, such as the three-year follow-up trial in South Africa, demonstrate that protection from the Vi vaccine wanes more rapidly compared to the oral live-attenuated Ty21a vaccine, with booster recommendations reflecting this shorter duration of approximately 2 years for Vi versus 5 years for Ty21a in at-risk populations.

Adverse effects

The Vi capsular polysaccharide (ViCPS) vaccine is generally well-tolerated, with most adverse effects being mild and transient. Common local reactions at the injection site include pain, tenderness, redness (), and swelling (induration), typically resolving within 1–7 days. These occur in approximately 10–40% of recipients, with pain reported in 18–41% and erythema or induration in 4–15% across clinical trials and post-marketing studies. Systemic adverse effects are less frequent and include mild fever (temperature <38°C), , (), , and , usually self-resolving within 1–2 days. Incidence rates range from 1–12% for fever and 1.5–20% for headache, with overall systemic reactions affecting 5–10% of vaccinees; these rates are comparable to those observed with other vaccines, such as pneumococcal or meningococcal. Rare serious adverse events include , estimated at approximately 1 per million doses based on vaccine surveillance data, and potential neurologic conditions like Guillain-Barré syndrome, though no confirmed causal association has been established with ViCPS vaccination. Other infrequently reported events, such as , syncope, or , have been noted in post-marketing surveillance but lack proven causality. The vaccine shows no association with infection or symptoms related to vaccine failure. Most reactions are self-limited and do not require medical intervention, though individuals should seek care for severe or persistent symptoms, such as high fever, difficulty breathing, or significant swelling. Adverse events can be reported to systems like the Vaccine Adverse Event Reporting System (VAERS) for ongoing monitoring.

Biological basis

Vi antigen structure

The Vi antigen, also known as the Vi capsular polysaccharide, is a linear homopolymer consisting of repeating units of α-1,4-linked N-acetyl-D-galactosaminuronic acid (GalNAcA) residues, with O-acetyl groups variably attached at the C-3 position of the sugar units. This structure confers the polysaccharide's antigenic properties and role as a key surface component of the bacterium. The Vi antigen is encoded by the viaB locus on the bacterial chromosome. In its native form, the Vi polysaccharide exhibits a high molecular weight, typically exceeding 2 million Da (e.g., around 3.5 million Da in some preparations), forming a dense capsular layer around the bacterial cell. For vaccine use, the antigen is purified into a soluble form with a reduced molecular weight of approximately 200 kDa to enhance immunogenicity and stability. The Vi antigen is produced by serovar Typhi, particularly the Ty2 strain, during bacterial growth in culture. As a major , it shields the bacterium by inhibiting complement activation and evading by host immune cells, thereby promoting systemic . Purification of the Vi polysaccharide begins with extraction from the culture supernatant of S. Typhi, followed by precipitation using or similar solvents to isolate the , and further refinement via techniques such as size-exclusion or anion-exchange to achieve high purity. The Vi demonstrates good thermal stability, remaining intact at temperatures up to 37°C for extended periods, which supports its use in formulations stored under controlled conditions. However, it is susceptible to degradation by strong acids or bases, which can hydrolyze the glycosidic bonds or remove O-acetyl groups. Preservative-free formulations of the purified Vi polysaccharide are available in licensed , relying on sterile, isotonic buffers for stability without added chemical preservatives.

Immunological mechanism

The Vi capsular polysaccharide vaccine functions as a T-cell-independent , directly stimulating B cells to produce primarily IgM and IgG anti-Vi antibodies without requiring T-helper cell involvement. This response occurs through cross-linking of B-cell receptors by the repetitive structure, leading to rapid but predominantly extrafollicular B-cell activation and short-lived differentiation. The protective mechanism relies on these anti-Vi antibodies, which opsonize Salmonella Typhi bacteria, facilitating their recognition and uptake by such as neutrophils and macrophages. By binding to the Vi capsule, the antibodies also counteract the capsule's antiphagocytic properties and restore complement deposition, thereby overcoming Vi-mediated serum resistance and promoting bacterial killing via complement-dependent mechanisms. Key correlates of immunity include serum bactericidal activity mediated by anti-Vi antibodies and elevated anti-Vi IgG levels, with thresholds of approximately 1.4–2.0 μg/mL associated with prevention of bloodstream invasion by S. Typhi. These functional antibodies inhibit bacterial dissemination from the gut to systemic sites, reducing the risk of severe . A major limitation of this immunological pathway is the absence of memory B-cell formation, resulting in no immunological and rapid waning of antibody titers within 2–3 years post-vaccination. Additionally, the vaccine elicits a poor response in infants under 2 years due to immature B-cell function and limited capacity for T-cell-independent responses. In comparison to other typhoid , the Vi polysaccharide vaccine induces a humoral response comparable in magnitude to the live oral vaccine, which elicits T-cell-dependent immunity with memory formation, though it is safer than historical whole-cell killed vaccines due to lower reactogenicity.

History and development

Early research

The Vi antigen, a capsular serving as a major in serovar Typhi, was first identified in the 1930s by A. Felix and R.M. Pitt through serological studies demonstrating its role in conferring resistance to bactericidal activity in serum and its association with aggressive typhoid infections. Their in the 1930s and 1940s established that strains expressing the Vi antigen were more virulent in animal models and human cases compared to non-expressing variants, laying the groundwork for targeting this structure in development. By the , additional bacteriological investigations confirmed the antigen's exclusivity to S. Typhi and S. Paratyphi C, highlighting its potential as a specific for typhoid prevention. In the , Maurice Landy contributed significantly to the practical isolation of Vi polysaccharide, developing extraction methods from S. Typhi cultures that preserved its immunological properties while separating it from other bacterial components. These techniques involved acetic acid precipitation and purification steps to yield a stable suitable for testing. Landy's work shifted focus toward subunit vaccines, moving away from earlier whole-cell preparations that caused significant reactogenicity. Animal studies in the 1970s further validated the protective potential of purified Vi polysaccharide; for instance, immunization of mice with the antigen conferred resistance to lethal S. Typhi challenges, with survival rates exceeding 80% in protected groups compared to controls. These experiments demonstrated dose-dependent immunity mediated by Vi-specific antibodies, supporting the antigen's role in blocking bacterial invasion and dissemination. Concurrently, purification challenges were addressed through the use of detergents like cetyltrimethylammonium bromide (cetavlon), which enabled high-yield extraction of Vi largely free of contaminating lipopolysaccharides and endotoxins, reducing pyrogenicity and improving safety over whole-cell vaccines. This refinement was crucial, as residual endotoxins in early extracts caused fever and inflammation in preclinical models, prompting the transition to a purified subunit approach for human application. Early human trials in the marked a pivotal advancement. A 1987 randomized trial in involving approximately 6,900 participants aged 5–44 years demonstrated 72% protective efficacy against culture-confirmed over 18 months of follow-up. This was followed by a double-blind, randomized field trial in involving 23,075 schoolchildren showing that a single 25 μg dose of Vi vaccine provided 64% protective efficacy against culture-confirmed starting 6 weeks post-vaccination, sustained over 21 months of surveillance. The trial reported 19 cases among 11,384 vaccinated children versus 47 in the control group, underscoring the vaccine's ability to reduce incidence in endemic settings. Studies in the late confirmed its in adults, with approximately 88% achieving and substantial rises in anti-Vi titers persisting for at least 12 months. Pre-licensing trials in the late 1980s and early 1990s, conducted across endemic sites including and , demonstrated the vaccine's safety profile in tens of thousands of participants, with adverse events limited to mild local reactions in less than 5% of recipients and no serious systemic effects observed. These evaluations, involving randomized controlled designs, affirmed the vaccine's tolerability in children over 2 years and adults, paving the way for regulatory approval while highlighting the need for boosters due to waning immunity after 2–3 years.

Licensing milestones

The Vi capsular polysaccharide vaccine received its first regulatory approval in the United States in 1994, when the FDA licensed Typhim Vi, manufactured by Pasteur Mérieux (now ), for active immunization against in persons aged 2 years and older. In the late 1990s, the approved Typherix, a Vi vaccine produced by GlaxoSmithKline, marking expanded availability in Europe for similar indications in individuals aged 2 years and older. During the 2000s, the vaccine was integrated into recommendations by the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) for at-risk groups, including travelers to endemic areas, close contacts of typhoid carriers, and laboratory workers handling Salmonella Typhi; this built on the initial 1994 ACIP guidance without altering the core eligibility for persons aged 2 years and older. Approvals also expanded in during this period, supporting broader use in high-burden regions. In the 2010s, the vaccine saw integration into targeted national programs in endemic countries; for example, conducted large-scale Vi polysaccharide vaccination campaigns, such as the 2010 effort in delivering over 64,000 doses to children aged 2 years and older in high-risk areas, while some states like incorporated it into routine for schoolchildren. Similarly, implemented school-based Vi polysaccharide campaigns, including a 2006 initiative in vaccinating primary school children through existing platforms, with ongoing use in outbreak-prone areas. The International Vaccine Institute supported demonstration projects and stockpiling efforts for Vi-based vaccines to facilitate access in low-resource settings during this decade. In the 2020s, the reaffirmed the role of Vi polysaccharide vaccines in its 2018 , recommending their programmatic use for typhoid control in endemic areas and travelers aged 2 years and older, with efficacy estimated at 55–65% for 2–3 years, even as typhoid conjugate vaccines emerged as the preferred option for younger children and routine programs; no major regulatory revocations have occurred as of 2025.

Formulations

Composition and manufacturing

The Vi capsular polysaccharide vaccine contains 25 μg of purified Vi polysaccharide derived from Salmonella enterica serovar Typhi as the active ingredient per 0.5 mL dose. This polysaccharide is a linear polymer of α-1,4-linked N-acetylgalactosaminuronic acid, briefly referencing its for context in . The includes excipients such as for isotonicity, a buffer to maintain around 7, and 0.25% phenol as a to prevent microbial growth; notably, the vaccine contains no adjuvants or antibiotics. Manufacturing commences with the fermentation of the S. Typhi Ty2 strain in a controlled semi-synthetic medium to promote capsular production. The culture supernatant is then processed through to separate the capsular material, followed by purification involving with a cationic detergent like hexadecyltrimethylammonium bromide (cetavlon), alcohol to isolate the , and for further refinement and concentration, ensuring removal of impurities such as proteins, nucleic acids, and endotoxins. The purified bulk is diluted to the target concentration, terminally filtered for sterility, and aseptically filled into single-dose vials or prefilled syringes. Quality assurance adheres to WHO prequalification standards, which mandate rigorous controls throughout production, including validation of the seed lot, fermentation conditions, and purification yields. Lot release testing encompasses potency evaluation via to quantify Vi antigen levels and O-acetyl content, alongside assays for sterility, pyrogenicity (using the test), identity, and residual impurities to confirm safety and efficacy. Variations exist across manufacturers; some formulations omit preservatives like phenol for single-dose presentations, while the standard is 2-3 years when stored refrigerated at 2-8°C, with stability confirmed through accelerated degradation studies.

Trade names and availability

The primary trade names for the Vi capsular polysaccharide vaccine are Typhim Vi, manufactured by and primarily available in the United States and , and Typherix, previously produced by GlaxoSmithKline (GSK) for international markets but discontinued in many countries since 2018. Local production includes Shantyph by Shantha Biotec in , which was acquired by in 2009 and contributes to supply in . The is widely distributed in over 100 countries. It is accessible through national programs and private markets in endemic regions, though uptake remains limited compared to conjugate alternatives due to age restrictions and duration of protection. While previously WHO-prequalified (e.g., Typhim Vi in ), ViCPS formulations are no longer prequalified, with preference given to typhoid conjugate (TCVs) for routine in endemic areas as of 2025. In developed markets, the cost per dose ranges from $80 to $250, depending on retail or clinic pricing. In endemic areas like , prices are substantially lower, with single-dose vials such as Shantyph available for approximately $2–3 through local manufacturers and subsidized procurement. Bulk procurement via international organizations supports access in low-income settings, often at $0.50–$5 per dose. As of 2025, the global supply chain for Vi capsular vaccines remains stable, with no reported shortages following disruptions during the ; major manufacturers like maintain consistent production and distribution.

Ongoing research

Conjugate vaccine advancements

Conjugation of the Vi capsular to carrier proteins, such as toxoid or toxoid (CRM197), transforms the from T-cell independent to T-cell dependent, enabling the production of immunological memory, higher titers, and efficacy in infants under 2 years of age who do not respond well to plain vaccines. This approach addresses the limitations of the plain Vi vaccine, which induces only short-lived antibodies without T-cell involvement, making conjugates suitable for routine immunization programs targeting young children in endemic areas. A prominent example is Typbar-TCV, developed by , which conjugates Vi polysaccharide to tetanus toxoid (Vi-TT) and was the first typhoid conjugate vaccine to receive WHO prequalification on December 22, 2017. Clinical trials demonstrated its efficacy at 79-84% in preventing among children aged 9 months to 16 years following a single dose, with robust and safety profiles across age groups. Another early conjugate, Vi-rEPA, links Vi to recombinant exoprotein A and showed 89% efficacy in phase II/III trials among 2- to 5-year-olds in during the 2000s, establishing proof-of-concept for conjugate technology in high-burden settings. Typbar-TCV was initially licensed in in 2013 and prequalified by WHO in 2017, paving the way for broader global access in endemic countries, and has since been licensed in several countries including , , and . As of , approximately 8 million doses of Typbar-TCV had been administered in mass campaigns across and , contributing to typhoid control efforts in countries like , , and . A 2024 Lancet study provided long-term data on Typbar-TCV from a phase 3 in Malawian children, confirming 78.3% overall (95% CI 66.3–86.1) over a 4.3 years of follow-up, with efficacy ranging from 70.6% in 9-month to 2-year-olds to 79.3% in 5- to 12-year-olds. The analysis revealed minimal waning, with an estimated annual decline of 1.3% (95% CI –9.8 to 7.2, p=0.77), supporting its durability and single-dose regimen for sustained protection in endemic regions. In November 2025, phase 3 trial results for EuTYPH-C, a new Vi-DT by EuBiologics, confirmed its safety and non-inferior compared to Typbar-TCV in participants aged 6 months to 45 years across and , supporting potential future expansion of TCV options.

Comparative studies and challenges

Head-to-head clinical trials have compared the Vi capsular polysaccharide (ViCPS) vaccine with the oral live-attenuated vaccine, revealing similar short-term rates of 50-80% against culture-confirmed in adults and children over 2 years old. However, ViCPS demonstrates a faster onset of protection, typically within 7-14 days post-vaccination due to its single injectable dose, compared to Ty21a, which requires three to four doses over a week and achieves peak immunity around 3 weeks. In contrast, comparisons with typhoid conjugate vaccines (TCVs) highlight ViCPS limitations in young children; it shows limited and (often <50%) in infants under 2 years, whereas TCVs achieve 70-80% in this age group by eliciting T-cell dependent responses.02031-7/fulltext) Implementation of ViCPS faces significant challenges, including the need for a strict (2-8°C storage) that is difficult to maintain in tropical regions with unreliable and . Cost barriers further limit access in low-income countries, where the price (around $10-15 per dose) exceeds affordable thresholds without subsidies, restricting widespread use. Additionally, gaps in typhoid underestimate the true , complicating targeted deployment and evaluation of vaccine impact. Recent studies from 2020-2025, including post-marketing surveillance of Typbar-TCV in and , have confirmed 76% effectiveness against culture-confirmed in children during outbreaks. Mathematical modeling of mass vaccination campaigns with TCVs predicts typhoid incidence reductions of 40-90% over several years, depending on coverage and setting, underscoring potential for substantial gains. Future hurdles for ViCPS and typhoid vaccines include rising antimicrobial resistance in Salmonella Typhi, which necessitates vaccines to curb transmission and preserve antibiotic efficacy. Broader serovar coverage is needed, as current vaccines primarily target S. Typhi and offer limited protection against paratyphoid strains. Integration into routine schedules remains essential for sustained impact, particularly in endemic areas. Economic analyses indicate that TCVs are more cost-effective than ViCPS in endemic settings, with incremental cost-effectiveness ratios (ICERs) often below $100 per disability-adjusted life-year (DALY) averted when including catch-up campaigns.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK470571/
  2. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a4.htm
  3. https://pubmed.ncbi.nlm.nih.gov/10534182/
  4. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/typhoid-and-paratyphoid-fever.html
  5. https://www.cdc.gov/vaccines/hcp/current-vis/typhoid.html
  6. https://www.cdc.gov/Mmwr/preview/mmwrhtml/00001710.htm
  7. https://www.drugs.com/pro/typhim-vi.html
  8. https://www.thelancet.com/journals/lancet/article/PIIS014067368791316X/fulltext
  9. https://www.fda.gov/media/75993/download
  10. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/typhoid-vaccines
  11. https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html
  12. https://www.cdc.gov/yellow-book/hcp/travelers-with-additional-considerations/immunocompromised-travelers.html
  13. https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html
  14. https://www.ncbi.nlm.nih.gov/books/NBK501132/
  15. https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/vaccination-and-immunoprophylaxis-general-principles.html
  16. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/typhoid
  17. https://www.medicines.org.uk/emc/product/1393/smpc
  18. https://www.cdc.gov/vaccines/hcp/administration/after.html
  19. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-23-typhoid-vaccine.html
  20. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/621271
  21. https://pubmed.ncbi.nlm.nih.gov/2890805/
  22. https://www.nejm.org/doi/full/10.1056/NEJMoa0807521
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4604742/
  24. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00606-X/fulltext
  25. https://www.nature.com/articles/s41541-022-00434-8
  26. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1139329/full
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4018880/
  28. https://pubmed.ncbi.nlm.nih.gov/17636661/
  29. https://pubmed.ncbi.nlm.nih.gov/20003920/
  30. https://www.frontiersin.org/journals/tropical-diseases/articles/10.3389/fitd.2021.709745/full
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7142696/
  32. https://journals.asm.org/doi/10.1128/CVI.00532-10
  33. https://europepmc.org/article/pmc/4034380
  34. https://pubmed.ncbi.nlm.nih.gov/8735556/
  35. https://cdn.who.int/media/docs/default-source/pvg/global-vaccine-safety/typhoid-vaccine-rates-information-sheet.pdf?sfvrsn=706de51b_4
  36. https://www.cdc.gov/mmwr/pdf/rr/rr4314.pdf
  37. https://www.sciencedirect.com/science/article/pii/S0264410X19306747
  38. https://www.pnas.org/doi/10.1073/pnas.1524665113
  39. https://journals.asm.org/doi/pdf/10.1128/iai.59.12.4555-4561.1991
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4100779/
  41. https://patents.google.com/patent/EP3335727A1/en
  42. https://www.sanofi.com/assets/countries/canada/docs/products/vaccines/typhim-en-032824.pdf
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3028862/
  44. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2019.00141/full
  45. https://www.sciencedirect.com/science/article/pii/S1877282X10000159
  46. https://www.researchgate.net/publication/288374777_Optimization_of_procedure_for_purification_of_typhoid_Vi_polysaccharide_by_column_chromatography
  47. https://pubmed.ncbi.nlm.nih.gov/34442786/
  48. https://pubs.acs.org/doi/10.1021/acs.analchem.9b05107
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC7388714/
  50. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145945
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4068246/
  52. https://rupress.org/jem/article/218/2/e20201116/211531/Vi-specific-serological-correlates-of-protection
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC7055164/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC3620468/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC98400/
  56. https://www.sciencedirect.com/science/article/pii/S0020245297860186
  57. https://link.springer.com/chapter/10.1007/978-1-4615-2854-8_13
  58. https://journals.sagepub.com/doi/abs/10.3181/00379727-80-19520
  59. https://www.jstor.org/stable/4454930
  60. https://www.sciencedirect.com/science/article/abs/pii/S0264410X13011286
  61. https://www.nejm.org/doi/full/10.1056/NEJM198710293171801
  62. https://www.sciencedirect.com/science/article/pii/S014067368791316X
  63. https://pubmed.ncbi.nlm.nih.gov/2244290
  64. https://www.cdc.gov/mmwr/preview/mmwrhtml/00035643.htm
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC10644681/
  66. https://pubmed.ncbi.nlm.nih.gov/17005220/
  67. https://www.who.int/publications-detail-redirect/typhoid-vaccines-who-position-paper-march-2018
  68. https://pubmed.ncbi.nlm.nih.gov/23994374/
  69. http://www.biomed.co.in/wp-content/uploads/2017/12/PPD-BIO-TYPH-I.P..pdf
  70. https://www.who.int/publications/m/item/vi-polysaccharide-typhoid-vaccine-annex-1-trs-no-840
  71. https://www.sanofi.com/assets/countries/south-africa/docs/typhim-information.pdf
  72. https://www.fda.gov/vaccines-blood-biologics/vaccines/typhim-vi
  73. https://www.coalitionagainsttyphoid.org/the-issues/typhoid-vaccines/
  74. https://www.1mg.com/drugs/shantyph-25mcg-vaccine-412330
  75. https://bettercare.com/costs/typhoid-vaccine-cost
  76. https://www.cdc.gov/vaccines/hcp/vaccines-us/shortages-delays.html
  77. https://www.sciencedirect.com/science/article/pii/S0264410X19313027
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10076549/
  79. https://www.who.int/docs/default-source/biologicals/call-for-comments/tcv-recommendations-final-3-april-2020.pdf?sfvrsn=f0fabdc9_2
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC7533886/
  81. https://extranet.who.int/prequal/vaccines/p/typbar-tcv-0
  82. https://www.nejm.org/doi/full/10.1056/NEJMoa2035916
  83. https://academic.oup.com/jid/article/224/Supplement_7/S788/6371004
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC523060/
  85. https://journals.asm.org/doi/10.1128/iai.67.11.5806-5810.1999
  86. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02031-7/fulltext
  87. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00330-4/fulltext
  88. https://www.sciencedirect.com/science/article/pii/S2214109X2300606X
  89. https://www.researchgate.net/publication/389165337_Barriers_to_Cost-Effective_Typhoid_Vaccination_Implementation_in_Uganda_Challenges_and_Opportunities
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC8917043/
  91. https://www.coalitionagainsttyphoid.org/the-issues/vaccines/challenges/
  92. https://www.sciencedirect.com/science/article/pii/S2214109X21002552
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC9880559/
  94. https://www.sciencedirect.com/science/article/pii/S0264410X23006277
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC10236512/
  96. https://www.coalitionagainsttyphoid.org/typhoid-burden-challenges-and-the-promise-of-typhoid-conjugate-vaccines/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC5462484/
Add your contribution
Related Hubs
User Avatar
No comments yet.